Skip to main content

Table 1 Comparative analysis of full-field electroretinography (ERG) responses

From: Preclinical assessment of intravitreal ramucirumab: in vitro and in vivo safety profile

  Rods Combined A Combined B Cone A Cone B Flicker
Baseline Follow-up P-value Baseline Follow-up P-value Baseline Follow-up P-value Baseline Follow-up P-value Baseline Follow-up P-value Baseline Follow-up P-value
C1–C4
 OD 83.1 (54.0–119.0) 155.5 (103.0–162.0) 0.0679 42.5 (36.7–70.5) 52.3 (44.7–61.9) 0.4652 146.0 (84.3–165.0) 202.5 (119.0–241.0) 0.0679 10.1 (6.2–15.3) 9.5 (7.8–12.8) 0.4652 105.0 (61.7–115.0) 94.8 (63.7–118.0) 0.9999 66.0 (48.3–77.8) 76.5 (42.3–94.1) 0.4652
 OS 69.8 (34.2–134.0) 185.5 (153.0–251.0) 0.0679 36.5 (23.4–71.7) 72.3 (45.1–80.5) 0.0679 135.0 (80.4–163.0) 227.5 (188.0–301.0) 0.0679 8.6 (6.3–11.7) 8.9 (5.4–17.4) 0.4652 97.7 (60.5–111.0) 102.3 (70.1–176.0) 0.0679 54.1 (32.1–75.2) 95.1 (64.7–115.0) 0.0679
C5–C8
 OD 108.2 (16.9–160.0) 154.5 (135.0–205.0) 0.0679 50.8 (10.5–62.8) 62.0 (60.1–64.9) 0.0679 146.0 (27.8–181.0) 178.0 (151.0–205.0) 0.0679 7.2 (1.8–10.6) 10.4 (7.9–13.6) 0.0679 63.8 (12.7–86.3) 99.7 (65.8–127.0) 0.1441 66.7 (6.24–81.0) 79.3 (72.1–104.0) 0.0679
 OS 115.7 (51.6–207.0) 142.5 (84.0–188.0) 0.5807 53.1 (28.4–87.1) 61.7 (40.3–69.8) 0.715 148.0 (79.2–236.0) 179.0 (118.0–217.0) 0.4652 8.5 (5.9–11.0) 9.3 (7.2–13.4) 0.2733 69.6 (53.7–100.0) 74.1 (71.4–129.0) 0.1441 67.5 (25.7–110.0) 61.9 (50.5–82.2) 0.715
C9–C11
 OD 101.0 (37.3–104.0) 101.0 (93.5–156.0) 0.285 44.7 (40.2–60.3) 58.7 (39.7–68.8) 0.9999 134.0 (57.8–160.0) 169.0 (147.0–234.0) 0.1088 9.1 (7.5–9.5) 10.1 (8.9–11.9) 0.1088 86.2 (63.9–99.8) 108.0 (90.9–132.0) 0.1088 61.9 (42.7–72.0) 63.5 (58.4–69.0) 0.593
 OS 117.0 (26.9–119.0) 133.0 (96.7–179.0) 0.1088 46.7 (35.5–51.4) 63.2 (33.3–82.3) 0.285 113.0 (54.7–169.0) 208.0 (125.0–238.0) 0.1088 11.3 (5.7–11.8) 11.6 (11.2–14.8) 0.285 85.7 (52.1–110.0) 91.6 (79.7–107.0) 0.285 56.6 (34.0–89.1) 88.4 (68.8–89.6) 0.1088
C12–C16
 OD 105.0 (93.3–163.0) 113.0 (94.7–170.0) 0.9999 57.7 (49.2–62.7) 42.1 (37.5–50.3) 0.285 143.0 (133.0–154.0) 127.0 (126.0–173.0) 0.9999 7.4 (7.0–7.6) 8.1 (4.5–8.3) 0.9999 74.1 (60.5–86.2) 52.7 (48.4–89.7) 0.285 50.9 (49.4–71.7) 51.6 (33.4–71.7) 0.9999
 OS 114.0 (99.5–175.0) 108.0 (108.0–110.0) 0.593 58.6 (55.6–69.1) 43.3 (34.9–46.8) 0.1088 165.0 (134.0–177.0) 131.0 (128.0–132.0) 0.1088 8.6 (8.4–11.1) 6.7 (5.0–7.1) 0.1088 95.7 (65.7–99.6) 59.0 (51.2–75.3) 0.1088 71.6 (57.6–84.0) 48.6 (45.0–56.5) 0.1088
  1. Full-field ERG amplitude in rabbits injected with ramucirumab in the right eye (OD) or BSS in the left eye (OS). Values of amplitude presented as median (range). Statistical analysis was performed using Wilcoxon signed-rank test. C1–C4 (500 µg group with 24 h of follow-up); C5–C8 (500 µg group with 7 days of follow-up); C9–C11 (250 µg group with 24 h of follow-up); C12–C16 (250 µg group with 7 days of follow-up)